Physician profile
Philip Eugene Short
NPI 1598741597
$10,947.64
in general payments reported to CMS, 2019-2025
50 companies · $1,525 in 2025
The $1,525 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,835 · 2020: $726 · 2021: $1,006 · 2022: $1,144 · 2023: $1,832 · 2024: $880 · 2025: $1,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,236.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,573.82 | 2019-2022 | |
| Abbvie INC. | $1,439.30 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals Lp | $1,387.05 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $848.68 | 2019-2023 | Mounjaro, Jardiance |
| Alkermes, INC. | $639.67 | 2019-2025 | Lybalvi |
| Amarin Pharma, INC. | $532.79 | 2019-2020 | |
| Novo Nordisk INC | $483.72 | 2019-2025 | Wegovy, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $447.65 | 2022-2025 | Cobenfy, Opdivo, Camzyos |
| Axsome Therapeutics, INC. | $294.66 | 2023 | Auvelity |
| Allergan, INC. | $289.78 | 2019 | |
| Glaxosmithkline, LLC. | $269.43 | 2019-2024 | Shingrix |
| Janssen Pharmaceuticals, INC | $252.62 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.29 | 2019-2024 | Xifaxan |
| Neurocrine Biosciences, INC. | $215.37 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $209.44 | 2019-2020 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Short listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.